Recombinant factor VIIa (NovoSeven®) and the safety of treatment
HR Roberts - Seminars in hematology, 2001 - Elsevier
Recombinant factor VIIa (rFVIIa; NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark) has
been used to treat more than 6,500 patients with hemophilia or other bleeding disorders,
and by May 2001, more than 180,000 standard doses had been administered. Clinical
experience to date suggests that rFVIIa is safe and effective, with a very low incidence of
thrombotic events being reported. Moreover, in the majority of cases, thrombotic events
appear to be caused by improvements in the hemostatic system, rather than a direct effect of …
been used to treat more than 6,500 patients with hemophilia or other bleeding disorders,
and by May 2001, more than 180,000 standard doses had been administered. Clinical
experience to date suggests that rFVIIa is safe and effective, with a very low incidence of
thrombotic events being reported. Moreover, in the majority of cases, thrombotic events
appear to be caused by improvements in the hemostatic system, rather than a direct effect of …